AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9491571 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 0
Study 8173852 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 h bed rest following intra-articular steroid injection
Number of subjects: 91
Study 8173852 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient injections (no rest)
Number of subjects: 91
Study 3224402 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin + Amikacin (P + A)
Number of subjects: 71
Study 3224402 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime + Amikacin (C + A)
Number of subjects: 71
Study 31410518 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 158
Study 31410518 — intervention group
Group type: COMPARATOR
Intervention: TVT-Abbrevo
Number of subjects: 158
Study 31410518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study 29975624 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-Free Survival (PFS)
Number of subjects: 7507
Study 29975624 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-Free Survival at 24 months (PFS24)
Number of subjects: 7507
Study 29975624 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate threshold effect for PFS
Number of subjects: 7507
Study 29975624 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate threshold effect for PFS24
Number of subjects: 7507
Study 26997308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided technique
Number of subjects: 80
Study 26997308 — intervention group
Group type: COMPARATOR
Intervention: Non-guided approach
Number of subjects: 80
Study 24018781 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/amlodipine combination 20/5 mg
Number of subjects: 276
Study 24018781 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg
Number of subjects: 276
Study 24018781 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 276
Study 23446066 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/advice plus an 8-week pedometer-driven walking program (EWP, n=40)
Number of subjects: 57
Study 23446066 — intervention group
Group type: COMPARATOR
Intervention: Education/advice (E, n=17)
Number of subjects: 57
Study 20957980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (0.3, 3, or 10 mg/kg)
Number of subjects: 453
Study 20957980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (phase III study)
Number of subjects: 453
Study 20957980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (all doses)
Number of subjects: 453
Study 19025266 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 400
Study 16368302 — intervention group
Group type: EXPERIMENTAL
Intervention: Resynchronization by LV pacing alone
Number of subjects: 29
Study 12590027 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and exercise training programs
Number of subjects: 92
Study 10916104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-modified, regenerated cellulose (CL-E) membrane
Number of subjects: 0
Study 10916104 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) membrane
Number of subjects: 0
Study 10916104 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 0
Study 10916104 — intervention group
Group type: COMPARATOR
Intervention: Cellulosic membrane
Number of subjects: 0
Study 10916104 — intervention group
Group type: COMPARATOR
Intervention: Cellulose membrane
Number of subjects: 0
Study 10916104 — intervention group
Group type: EXPERIMENTAL
Intervention: CL-E membrane
Number of subjects: 0
Study 10916104 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic membranes
Number of subjects: 0
Study 10916104 — intervention group
Group type: EXPERIMENTAL
Intervention: CL-E or synthetic membrane
Number of subjects: 0
Study 8750567 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 107
Study 8750567 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 107
Study 1556836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of BCG Tokyo 172 strain (80 mg in 40 ml saline, once a week for 8 weeks)
Number of subjects: 157
Study 1556836 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with BCG (40 mg in 40 ml saline, monthly for 12 months)
Number of subjects: 157
Study 1556836 — intervention group
Group type: COMPARATOR
Intervention: Control group without any prophylactic instillation
Number of subjects: 157
Study 3901269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-FU
Number of subjects: 0
Study 31367384 — intervention group
Group type: EXPERIMENTAL
Intervention: SeptiFast (SF)
Number of subjects: 200
Study 31367384 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood cultures (BCs)
Number of subjects: 200
Study 28940961 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of metformin (MF+)
Number of subjects: 70
Study 28940961 — intervention group
Group type: COMPARATOR
Intervention: Withholding metformin (MF-)
Number of subjects: 70
Study 28053789 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream applied around participants' ankle during locomotor training (Pain group)
Number of subjects: 0
Study 28053789 — intervention group
Group type: COMPARATOR
Intervention: Control group (always pain-free)
Number of subjects: 0
Study 24615429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 ethyl esters (n-3 PUFA), 2-4 g daily for 12 weeks
Number of subjects: 60
Study 24615429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin and omega-3 ethyl esters (n-3 PUFA)
Number of subjects: 60
Study 24615429 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 23039306 — intervention group
Group type: EXPERIMENTAL
Intervention: VIH‐TAVIE™ intervention (web application with four interactive computer sessions of 20 to 30 minutes each)
Number of subjects: 232
Study 23039306 — intervention group
Group type: COMPARATOR
Intervention: Control group (list of websites of interest)
Number of subjects: 232
Study 23039306 — intervention group
Group type: EXPERIMENTAL
Intervention: VIH‐TAVIE™ intervention
Number of subjects: 232
Study 23039306 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study 20651615 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy (60 mg/m, day 1, q3 weeks)
Number of subjects: 60
Study 20651615 — intervention group
Group type: COMPARATOR
Intervention: Combination of docetaxel (40 mg/m, day 1, q3 weeks) and S-1 (80 mg/m, days 1-15)
Number of subjects: 60
Study 20651615 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy
Number of subjects: 60
Study 20651615 — intervention group
Group type: COMPARATOR
Intervention: Combination of docetaxel and S-1
Number of subjects: 60
Study 17560879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (10/10, 10/20, 10/40, or 10/80 mg)
Number of subjects: 0
Study 17560879 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10, 20, 40, or 80 mg)
Number of subjects: 0
Study 17560879 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10, 20, 40, or 80 mg)
Number of subjects: 0
Study 16018379 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxomucil (2 sachets, 3.26 g plantago ovata, twice daily for 20 days)
Number of subjects: 60
Study 16018379 — intervention group
Group type: COMPARATOR
Intervention: Glycerin oil (control group)
Number of subjects: 60
Study 11755835 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% in the morning and placebo in the evening
Number of subjects: 20
Study 11755835 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 20
Study 11755835 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 20
Study 11755835 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 20
Study 11755835 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg four times a day
Number of subjects: 20
Study 9840561 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive gravity outflow
Number of subjects: 40
Study 9840561 — intervention group
Group type: COMPARATOR
Intervention: Direct connection of the outflow to wall suction
Number of subjects: 40
Study 8136666 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamolenic acid (evening primrose oil)
Number of subjects: 56
Study 8136666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (liquid paraffin)
Number of subjects: 56
Study 2914474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen therapy at 2 L/min
Number of subjects: 17
Study 2914474 — intervention group
Group type: COMPARATOR
Intervention: Nasal air therapy
Number of subjects: 17
Study 30317291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous dexamethasone
Number of subjects: 60
Study 30317291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg dexamethasone infiltrated into the peritonsillar regions
Number of subjects: 60
Study 30317291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL of 0.5% bupivacaine infiltration
Number of subjects: 60
Study 30317291 — intervention group
Group type: COMPARATOR
Intervention: Peritonsillar saline infiltration
Number of subjects: 60
Study 28259181 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic count of 1‐2)
Number of subjects: 96
Study 28259181 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 96
Study 25819584 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-ART
Number of subjects: 22
Study 24968533 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 40
Study 20797686 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pairs presented alone or with filler pairs
Number of subjects: 0
Study 20797686 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pairs with variability in congruity of components
Number of subjects: 0
Study 18432173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy followed by drug-eluting stent implantation (Rota-DES)
Number of subjects: 0
Study 18432173 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent implantation alone (DES)
Number of subjects: 0
Study 16150034 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based learning (CBL) programme covering cardiovascular drug therapy (n = 70)
Number of subjects: 167
Study 16150034 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional teaching) (n = 97)
Number of subjects: 167
Study 12829911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) monotherapy
Number of subjects: 25
Study 12829911 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine + prednisolone dual therapy
Number of subjects: 25
Study 10827214 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg folate/d
Number of subjects: 33
Study 10827214 — intervention group
Group type: EXPERIMENTAL
Intervention: 415 microg folate/d (as diet plus FA or a combination of FA and OJ)
Number of subjects: 33
Study 10827214 — intervention group
Group type: COMPARATOR
Intervention: Moderately folate-deplete diet (118 microg/d)
Number of subjects: 33
Study 8878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 78
Study 8878711 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 78
Study 8878711 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 2071268 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole salicylate (750 mg t.i.d.)
Number of subjects: 31
Study 2071268 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg t.i.d.)
Number of subjects: 31
Study 6191495 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 0
Study 6191495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin
Number of subjects: 0
Study 6191495 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-acne medications (other than salicylic acid and tretinoin)
Number of subjects: 0
Study 31442484 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid consisting of a video and ACP booklet
Number of subjects: 204
Study 31442484 — intervention group
Group type: COMPARATOR
Intervention: Cancer pain control
Number of subjects: 204
Study 28575208 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weekly doses of directly observed isoniazid and rifapentine (3HP)
Number of subjects: 3288
Study 26638010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every-2-weeks (Q2W)
Number of subjects: 305
Study 26638010 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg/day
Number of subjects: 305
Study 26638010 — intervention group
Group type: COMPARATOR
Intervention: Double-dose rosuvastatin
Number of subjects: 305
Study 26638010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 305
Study 26638010 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 305
Study 25129515 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% DEET topical repellent
Number of subjects: 4426
Study 25129515 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 4426
Study 23040580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 0
Study 19234056 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable diet (8 servings of vegetables, 2-3 servings of fruits)
Number of subjects: 30
Study 19234056 — intervention group
Group type: COMPARATOR
Intervention: Energy reduction diet (reduce daily intake by 500 kcal and limit energy from fat to <or=25%)
Number of subjects: 30
Study 19234056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high vegetable diet and energy reduction diet)
Number of subjects: 30
Study 16816279 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 560
Study 16816279 — intervention group
Group type: COMPARATOR
Intervention: Enhanced specialty referral
Number of subjects: 560
Study 12790845 — intervention group
Group type: EXPERIMENTAL
Intervention: Single combined preoperative dose of gentamicin (160 mg) and metronidazole (500 mg)
Number of subjects: 288
Study 12790845 — intervention group
Group type: COMPARATOR
Intervention: Postoperative standard scheme of antibiotics over 7 days
Number of subjects: 288
Study 12790845 — intervention group
Group type: EXPERIMENTAL
Intervention: Single combined preoperative dose of gentamicin and metronidazole
Number of subjects: 288
Study 10966992 — intervention group
Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study 10966992 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Number of subjects: 0
Study 8836419 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) as adjuvant after chemotherapy
Number of subjects: 0
Study 8836419 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) for partial responders (PRs) after chemotherapy
Number of subjects: 0
Study 8836419 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned XRT in advanced disease
Number of subjects: 0
Study 8836419 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) as salvage treatment for asymptomatic limited nodal relapse
Number of subjects: 0
Study 8836419 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT in high-dose therapy programs
Number of subjects: 0
Study 1734801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine 20 mg (group F2)
Number of subjects: 89
Study 1734801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine 20 mg (group F3)
Number of subjects: 89
Study 1734801 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular saline (placebo, group P2)
Number of subjects: 89
Study 1734801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular famotidine 20 mg (group F1)
Number of subjects: 89
Study 1734801 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular saline (placebo, group P3)
Number of subjects: 89
Study 6539662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg Gemeprost vaginal suppository
Number of subjects: 0
Study 6539662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31569168 — intervention group
Group type: EXPERIMENTAL
Intervention: Meth-ctDNA positive patients
Number of subjects: 146
Study 31569168 — intervention group
Group type: COMPARATOR
Intervention: Meth-ctDNA negative patients
Number of subjects: 146
Study 30891688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention-specific counseling (n = 35)
Number of subjects: 134
Study 30891688 — intervention group
Group type: COMPARATOR
Intervention: General weight counseling (n = 82)
Number of subjects: 134
Study 30891688 — intervention group
Group type: COMPARATOR
Intervention: No documented weight counseling (n = 17)
Number of subjects: 134
Study 30891688 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of provider empathy
Number of subjects: 134
Study 28341108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 every 3 weeks)
Number of subjects: 0
Study 28341108 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2 on day 1 every 3 weeks)
Number of subjects: 0
Study 27914473 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-E (20 sessions over 20 weeks)
Number of subjects: 132
Study 25089264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine (135 mg, twice daily)
Number of subjects: 115
Study 25089264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 25089264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine
Number of subjects: 115
Study 20934714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track (FT) program with fluid restriction and epidural analgesia (EDA)
Number of subjects: 151
Study 20934714 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) group
Number of subjects: 151
Study 19602962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic blockade with lidocaine
Number of subjects: 23
Study 19602962 — intervention group
Group type: COMPARATOR
Intervention: IV lidocaine
Number of subjects: 23
Study 17467553 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term azithromycin administration
Number of subjects: 0
Study 15896256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0
Study 12517685 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 12
Study 12517685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10705266 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg 3 times daily for 2 months
Number of subjects: 18
Study 10705266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8664560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 87
Study 8664560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 1283538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen
Number of subjects: 182
Study 1283538 — intervention group
Group type: COMPARATOR
Intervention: Untreated historical group
Number of subjects: 182
Study 1283538 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 182
Study 1283538 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 182
Study 6476499 — intervention group
Group type: EXPERIMENTAL
Intervention: 22% BCAA amino acid solution
Number of subjects: 22
Study 6476499 — intervention group
Group type: EXPERIMENTAL
Intervention: 41% BCAA amino acid solution
Number of subjects: 22
Study 6476499 — intervention group
Group type: COMPARATOR
Intervention: Control (41% BCAA amino acid solution)
Number of subjects: 22
Study 31639849 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot‐Assisted surgery (R)
Number of subjects: 26
Study 31639849 — intervention group
Group type: COMPARATOR
Intervention: Conventional Surgery (C)
Number of subjects: 26
Study 31462859 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized post with stud attachment
Number of subjects: 30
Study 31462859 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated access post
Number of subjects: 30
Study 31462859 — intervention group
Group type: COMPARATOR
Intervention: Cast coping (nonattachment control group)
Number of subjects: 30
Study 29958022 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop insulin delivery during labor and delivery
Number of subjects: 27
Study 29958022 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop insulin delivery postpartum
Number of subjects: 27
Study 29958022 — intervention group
Group type: COMPARATOR
Intervention: Comparison of maternal glucose concentration between mothers of infants with and without neonatal hypoglycemia
Number of subjects: 27
Study 28051828 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverdin‐Isham osteotomy (group A, 20 feet)
Number of subjects: 40
Study 28051828 — intervention group
Group type: COMPARATOR
Intervention: Endolog system (group B, 20 feet)
Number of subjects: 40
Study 24561397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (Gd-MRI) findings of enhancing herniated disc
Number of subjects: 204
Study 24561397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (Gd-MRI) findings of enhancing nerve root
Number of subjects: 204
Study 24561397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI (Gd-MRI) findings
Number of subjects: 204
Study 22659218 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 33
Study 19592029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg (group P)
Number of subjects: 45
Study 19592029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg added to lidocaine (group A)
Number of subjects: 45
Study 19592029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) solution (group S)
Number of subjects: 45
Study 16145678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow abnormality score decreased
Number of subjects: 377